S&P 500   4,320.23 (-2.04%)
DOW   33,957.11 (-1.19%)
QQQ   343.08 (-2.89%)
AAPL   158.20 (-2.12%)
MSFT   287.73 (-2.92%)
FB   300.73 (-2.58%)
GOOGL   2,543.85 (-2.76%)
AMZN   2,783.50 (-3.71%)
TSLA   908.09 (-2.36%)
NVDA   221.15 (-5.38%)
BABA   118.79 (-1.31%)
NIO   23.64 (-4.95%)
AMD   110.46 (-5.21%)
CGC   7.16 (-3.24%)
MU   80.71 (-2.70%)
GE   90.32 (-6.80%)
T   26.23 (-0.42%)
F   19.70 (-3.38%)
DIS   134.38 (-2.24%)
AMC   15.96 (-4.09%)
PFE   52.46 (+1.79%)
ACB   4.09 (-5.32%)
BA   200.43 (-1.85%)
S&P 500   4,320.23 (-2.04%)
DOW   33,957.11 (-1.19%)
QQQ   343.08 (-2.89%)
AAPL   158.20 (-2.12%)
MSFT   287.73 (-2.92%)
FB   300.73 (-2.58%)
GOOGL   2,543.85 (-2.76%)
AMZN   2,783.50 (-3.71%)
TSLA   908.09 (-2.36%)
NVDA   221.15 (-5.38%)
BABA   118.79 (-1.31%)
NIO   23.64 (-4.95%)
AMD   110.46 (-5.21%)
CGC   7.16 (-3.24%)
MU   80.71 (-2.70%)
GE   90.32 (-6.80%)
T   26.23 (-0.42%)
F   19.70 (-3.38%)
DIS   134.38 (-2.24%)
AMC   15.96 (-4.09%)
PFE   52.46 (+1.79%)
ACB   4.09 (-5.32%)
BA   200.43 (-1.85%)
S&P 500   4,320.23 (-2.04%)
DOW   33,957.11 (-1.19%)
QQQ   343.08 (-2.89%)
AAPL   158.20 (-2.12%)
MSFT   287.73 (-2.92%)
FB   300.73 (-2.58%)
GOOGL   2,543.85 (-2.76%)
AMZN   2,783.50 (-3.71%)
TSLA   908.09 (-2.36%)
NVDA   221.15 (-5.38%)
BABA   118.79 (-1.31%)
NIO   23.64 (-4.95%)
AMD   110.46 (-5.21%)
CGC   7.16 (-3.24%)
MU   80.71 (-2.70%)
GE   90.32 (-6.80%)
T   26.23 (-0.42%)
F   19.70 (-3.38%)
DIS   134.38 (-2.24%)
AMC   15.96 (-4.09%)
PFE   52.46 (+1.79%)
ACB   4.09 (-5.32%)
BA   200.43 (-1.85%)
S&P 500   4,320.23 (-2.04%)
DOW   33,957.11 (-1.19%)
QQQ   343.08 (-2.89%)
AAPL   158.20 (-2.12%)
MSFT   287.73 (-2.92%)
FB   300.73 (-2.58%)
GOOGL   2,543.85 (-2.76%)
AMZN   2,783.50 (-3.71%)
TSLA   908.09 (-2.36%)
NVDA   221.15 (-5.38%)
BABA   118.79 (-1.31%)
NIO   23.64 (-4.95%)
AMD   110.46 (-5.21%)
CGC   7.16 (-3.24%)
MU   80.71 (-2.70%)
GE   90.32 (-6.80%)
T   26.23 (-0.42%)
F   19.70 (-3.38%)
DIS   134.38 (-2.24%)
AMC   15.96 (-4.09%)
PFE   52.46 (+1.79%)
ACB   4.09 (-5.32%)
BA   200.43 (-1.85%)
NASDAQ:OPRX

OptimizeRx Stock Forecast, Price & News

$41.10
-2.30 (-5.30%)
(As of 01/25/2022 12:32 PM ET)
Add
Compare
Today's Range
$40.91
$42.90
50-Day Range
$41.97
$78.15
52-Week Range
$39.06
$99.18
Volume
3,068 shs
Average Volume
292,703 shs
Market Capitalization
$730.35 million
P/E Ratio
293.57
Dividend Yield
N/A
Beta
0.55
30 days | 90 days | 365 days | Advanced Chart
Receive OPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter.


OptimizeRx logo

About OptimizeRx

OptimizeRx Corp. is digital health company, which engages in the provision of digital health messaging via electronic health records, which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging; and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.

Headlines

OptimizeRx (NASDAQ:OPRX) Shares Gap Down to $53.21
January 14, 2022 |  americanbankingnews.com
OptimizeRx (NASDAQ:OPRX) Trading Down 5.1%
January 12, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:OPRX
Employees
2,018
Year Founded
N/A

Sales & Book Value

Annual Sales
$43.31 million
Cash Flow
$0.11 per share
Book Value
$3.31 per share

Profitability

Net Income
$-2.21 million
Pretax Margin
1.94%

Debt

Price-To-Earnings

Miscellaneous

Free Float
16,615,000
Market Cap
$730.35 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/09/2021
Today
1/25/2022
Next Earnings (Estimated)
2/23/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.45 out of 5 stars

Computer And Technology Sector

211th out of 435 stocks

Business Services, Not Elsewhere Classified Industry

33rd out of 67 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -












OptimizeRx (NASDAQ:OPRX) Frequently Asked Questions

Is OptimizeRx a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OptimizeRx stock.
View analyst ratings for OptimizeRx
or view top-rated stocks.

How has OptimizeRx's stock price been impacted by COVID-19 (Coronavirus)?

OptimizeRx's stock was trading at $7.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OPRX stock has increased by 447.3% and is now trading at $41.10.
View which stocks have been most impacted by COVID-19
.

When is OptimizeRx's next earnings date?

OptimizeRx is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for OptimizeRx
.

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) announced its quarterly earnings data on Tuesday, November, 9th. The company reported $0.09 EPS for the quarter, missing analysts' consensus estimates of $0.13 by $0.04. The company earned $16.13 million during the quarter, compared to the consensus estimate of $14.82 million. OptimizeRx had a trailing twelve-month return on equity of 2.03% and a net margin of 4.16%. During the same quarter last year, the company earned ($0.01) earnings per share.
View OptimizeRx's earnings history
.

What price target have analysts set for OPRX?

5 Wall Street analysts have issued 1-year price targets for OptimizeRx's shares. Their forecasts range from $54.00 to $112.00. On average, they expect OptimizeRx's stock price to reach $92.00 in the next year. This suggests a possible upside of 123.8% from the stock's current price.
View analysts' price targets for OptimizeRx
or view top-rated stocks among Wall Street analysts.

Who are OptimizeRx's key executives?

OptimizeRx's management team includes the following people:
  • Will Febbo, Chief Executive Officer & Director
  • Edward Stelmakh, Chief Operations & Financial Officer
  • Todd Inman, Chief Technology Officer
  • Marion K. Odence-Ford, Chief Compliance Officer & General Counsel
  • Angelo Campano, Senior Vice President & Principal-Agency Channels

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).

What is OptimizeRx's stock symbol?

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

Who are OptimizeRx's major shareholders?

OptimizeRx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.34%), New York State Teachers Retirement System (0.10%), State of Alaska Department of Revenue (0.07%), Precision Wealth Strategies LLC (0.06%), Louisiana State Employees Retirement System (0.05%) and Cutler Group LP (0.00%). Company insiders that own OptimizeRx stock include Douglas P Baker, Douglas P Baker, Ellen O'connor Vos, Gregory D Wasson, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo.
View institutional ownership trends for OptimizeRx
.

Which major investors are selling OptimizeRx stock?

OPRX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd.. Company insiders that have sold OptimizeRx company stock in the last year include Douglas P Baker, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, and William J Febbo.
View insider buying and selling activity for OptimizeRx
or view top insider-selling stocks.

Which major investors are buying OptimizeRx stock?

OPRX stock was bought by a variety of institutional investors in the last quarter, including New York State Teachers Retirement System, State of Alaska Department of Revenue, Louisiana State Employees Retirement System, Precision Wealth Strategies LLC, and Cutler Group LP. Company insiders that have bought OptimizeRx stock in the last two years include Ellen O'connor Vos, and Gregory D Wasson.
View insider buying and selling activity for OptimizeRx
or or view top insider-buying stocks.

How do I buy shares of OptimizeRx?

Shares of OPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptimizeRx's stock price today?

One share of OPRX stock can currently be purchased for approximately $41.10.

How much money does OptimizeRx make?

OptimizeRx has a market capitalization of $730.35 million and generates $43.31 million in revenue each year. The company earns $-2.21 million in net income (profit) each year or $0.14 on an earnings per share basis.

How many employees does OptimizeRx have?

OptimizeRx employs 2,018 workers across the globe.

What is OptimizeRx's official website?

The official website for OptimizeRx is www.optimizerx.com.

Where are OptimizeRx's headquarters?

OptimizeRx is headquartered at 400 WATER STREET SUITE 200, ROCHESTER MI, 48307.

How can I contact OptimizeRx?

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The company can be reached via phone at (248) 651-6568, via email at [email protected], or via fax at 248-453-5529.


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.